Stat5b expression inhibitor and its application

By discovering Stat5b as a potential marker for pancreatitis cancer and developing siRNA inhibitors, the problem of early diagnosis and intervention of pancreatitis cancer is solved, effectively inhibiting the transformation process of pancreatitis cancer, and providing new ideas for individualized treatment.

CN115702905BInactive Publication Date: 2024-12-03王理伟
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202110884329.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-08-03
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art is difficult to effectively predict and diagnose the early state of pancreatic cancer, and there is a lack of molecular mechanism research on the transformation of pancreatic cancer, resulting in a lack of effective methods for early intervention and individualized treatment of pancreatic cancer.

Method used

By studying the key nodes and related regulatory mechanisms of pancreatitis cancer transformation, Stat5b was found as a potential marker, and the expression inhibitor of Stat5b was developed. The siRNA sequence such as SEQ ID NO.1-4 was used to inhibit the expression of Stat5b to block pancreatitis. Malignant transformation of cancer.

Benefits of technology

Inhibition of Stat5b expression effectively inhibits the transformation process of pancreatitis cancer, providing a potential means for early intervention and diagnosis and treatment of pancreatic cancer, especially in the first stage, effectively block the progress of acinar duct epithelial metaplasia and reduce the transformation of ductal cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003193457290000051
    Figure BDA0003193457290000051
  • Figure HDA0003193457300000011
    Figure HDA0003193457300000011
Patent Text Reader

Abstract

The present invention discloses an expression inhibitor of Stat5b and an application thereof, and specifically discloses an application of the expression inhibitor of Stat5b in preparing a drug for treating pancreatitis and cancer. The expression inhibitor provided by the present invention inhibits the expression of Stat5b by interfering with Stat5b target points, thereby inhibiting the transformation of pancreatitis and cancer, and treating the first stage of pancreatic cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and specifically relates to an expression inhibitor of Stat5b and an application thereof, in particular to an application of the expression inhibitor of Stat5b in preparing a drug for treating pancreatitis and cancer. Background Art

[0002] Pancreatic cancer is one of the most malignant tumors and is known as the "king of cancers." Its incidence is rising rapidly around the world. Although surgical resection of the tumor provides the best option for prolonging survival, 85% of pancreatic cancer patients have already metastasized or are in the local advanced stage when diagnosed and cannot receive surgical treatment. The 5-year survival rate is only about 5%. Even if pancreatic cancer is diagnosed early and can receive surgical treatment, the median survival time is only about 15-19 months. Therefore, traditional early diagnosis methods or biomarkers are no longer suitable for the prediction of pancreatic cancer precursors or the diagnosis of pre-disease states. In 2010, Yachida's team published a major article in the journal Nature, sequencing DNA from tissue samples of primary and metastatic lesions (commonly liver, lung, and peritoneum) of seven patients with advanced pancreatic cancer. Through analysis of evolutionary genetics models, they found that the course of pancreatic cancer lasts an average of nearly 20 years and is divided into three stages: the first stage takes at least 10 years from the initial mutation in normal cells to non-metastatic adenocarcinoma cells; the second stage takes at least 5 years from non-metastatic to metastatic adenocarcinoma cells; the third stage takes 2-3 years from the beginning of metastasis to the death of the patient.

[0003] A large number of studies have shown that chronic pancreatitis is an independent risk factor for pancreatic cancer. Lowenfels et al. published an international multicenter case-control study that first clarified the exact link between chronic pancreatitis and pancreatic cancer. Patients with chronic pancreatitis have a greatly increased risk of pancreatic cancer, which can serve as an independent risk factor. Talamini et al. conducted a 10-year follow-up survey of patients with chronic pancreatitis and showed that the relative risk of pancreatic cancer increased significantly by 18.5 times. Therefore, early intervention in the process of pancreatitis-cancer transformation and finding potential markers for individualized treatment have become the research direction in recent years. However, there is currently a lack of corresponding scientific research on the molecular mechanism of pancreatitis-cancer transformation.

[0004] Early intervention in the process of pancreatitis-cancer transformation and finding potential markers for individualized treatment have become the research direction in recent years. However, there is a lack of corresponding scientific research on the molecular mechanism of pancreatitis-cancer transformation. Summary of the invention

[0005] The inventors have studied the key nodes of pancreatitis-cancer transformation and related regulatory mechanisms and discovered Stat5b, a potential marker for pancreatitis-cancer transformation, which provides a basis and new ideas for early intervention of pancreatic cancer and finding potential markers for individualized treatment. Currently, there is no research report that blocking Stat5b can treat pancreatitis-cancer transformation.

[0006] The inflammatory-cancer transformation that the present invention focuses on is the first stage, which provides the possibility for truly realizing early intervention and diagnosis and treatment of pancreatic cancer.

[0007] In order to solve the above technical problems, the present invention provides the following technical solutions:

[0008] The first aspect of the present invention relates to the use of a Stat5b expression inhibitor in the preparation of a drug for treating pancreatitis and cancer.

[0009] Wherein, the expression inhibitor inhibits the expression of Stat5b or reduces its expression level.

[0010] Preferably, the expression inhibitor is siRNA, and the sequence of the siRNA is preferably as shown in any one of SEQ ID NOs. 1-4.

[0011] In addition, the treatment of pancreatitis cancer in the present invention is preferably to inhibit the malignant transformation of pancreatitis cancer. The malignant transformation preferably refers to inhibiting the transformation of pancreatitis cancer into pancreatic cancer. In the present invention, the inhibition of the transformation of pancreatitis cancer into pancreatic cancer can be specifically manifested as: inhibiting the expression of Stat5b, a marker in the progression of acinar ductal metaplasia (ADM), thereby inhibiting the transformation of acinar cells into ductal cells, and at the same time affecting the expression of Krt 19, a marker of ductal cells.

[0012] In the present invention, the expression inhibitor may be the sole active ingredient or one of the effective ingredients of the drug.

[0013] The second aspect of the present invention relates to an expression inhibitor of Stat5b, wherein the expression inhibitor of Stat5b is siRNA; the sequence of the siRNA is shown in any one of SEQ ID NOs. 1 to 4.

[0014] The drugs involving the expression inhibitor of the present invention as active ingredients in the present invention can be prepared according to methods known in the art. The compounds of the present invention can be made into any dosage form suitable for human or animal use. The weight content of the compounds of the present invention in its pharmaceutical composition is usually 0.1 to 99.0%. In addition to the expression inhibitor, the drug can also include a pharmaceutically acceptable carrier.

[0015] The pharmaceutically acceptable carrier may be a conventional carrier in the art, and the carrier may be any suitable physiologically or pharmaceutically acceptable pharmaceutical excipient. The pharmaceutical excipient is a conventional pharmaceutical excipient in the art, preferably including a pharmaceutically acceptable excipient, filler or diluent, etc. More preferably, the pharmaceutical composition comprises 0.01 to 99.99% of the above protein and / or the above antibody-drug conjugate, and 0.01 to 99.99% of a pharmaceutical carrier, and the percentage is the mass percentage of the pharmaceutical composition.

[0016] Therefore, the present invention has previously studied the key nodes of pancreatitis-cancer transformation and the related regulatory mechanisms, and found that Stat5b, a potential marker of pancreatitis-cancer transformation, inhibits the expression of Stat5b and has an inhibitory effect on the early stage of pancreatic cancer transformation. That is, the positive and progressive effect of the present invention is to interfere with the Stat5b target, inhibit the expression of Stat5b, thereby inhibiting the pancreatitis-cancer transformation, and treat the first stage of pancreatic cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 Schematic diagram of the inhibition of ADM (acinar ductal metaplasia) in mice by interfering with Stat5b. A is the microscopic observation and counting diagram of the siRNA interference inhibition of the pancreatic ADM process in mice; the dark masses under the microscope in A are acinar cells, and the vacuolar ones are transformed ductal cells. B is the qPCR detection of the changes in the transcription levels of Stat5b and Krt 19 in the pancreatic ADM system of mice treated with siRNA. The siStat 5b-1 group is a mixture of SEQ ID NO: 1 and SEQ ID NO: 2 in equal proportions; siStat5b-2 is a mixture of SEQ ID NO: 3 and SEQ ID NO: 4 in equal proportions, and siCon is the control group. Specific embodiments

[0018] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples.

[0019] Example 1 Interference effect of siRNA on Stat5b

[0020] 1. Overview:

[0021] 1) Synthesize siRNA.

[0022] 2) Isolate mouse (Viton Lihua mouse C57bl / 6) acinar cells, transfect with siRNA using a transfection reagent to knock down Stat5b.

[0023] 3) Induce ADM in the system using TGF-α (transforming growth factor).

[0024] 4) Observe the effect of siRNA under a microscope and count cells with different morphologies.

[0025] 2. Required reagents

[0026] Culture medium: Waymouth (1) (GIBCO: 11220-035)

[0027] Transfection reagent: Lipofectamine TM RNAiMAX Transfection Reagent (GIBCO: 13778150)

[0028] TGF-α: 50 ng / ml (Peprotech)

[0029] Mouse tail Collagen I(YEASEN)

[0030] L-glutamine, (GIBCO: 25030081), HEPES (GIBCO: 15630080);

[0031] L-glutamate sodium salt (Sigma: 49621); pyruvate (Sigma: 8636); fumarate (Sigma: A3134); trypsin from soybean (Sigma: T6522);

[0032] Hyaluronidase (YEASEN: 20426ES60), EGTA (YEASEN 60339ES10); Collagenase type I (YEASEN: 40507ES60);

[0033] CaCl2.

[0034] 3. Preparation of reagents

[0035] Digestion solution I (5 ml / mouse): washing solution I + type I collagenase (3.75 mg) 0.75 mg / ml + hyaluronidase (7.5 mg) 1.5 mg / ml.

[0036] Digestion solution II (8 ml / mouse): storage solution + EGTA 80 μl (stock 200 mM, diluted to 2 mM).

[0037] Digestion solution III (5 ml / mouse): washing solution I + type I collagenase 6.25 mg (1.25 mg / ml) + hyaluronidase 10 mg (2 mg / ml).

[0038] Washing solution I (50 ml): storage solution + CaCl2 (1 M) 5 μl + MgCl2 (1 M) 60 μl.

[0039] Washing solution II: (50 ml): storage solution + CaCl2 (1M) 50 μl + MgCl2 (1M) 60 μl + albumin 2 g (4%).

[0040] The storage solution is shown in the following table:

[0041]

[0042] 4. Thin layer coating

[0043] Dilute Mouse Tail Collagen I to 50μg / ml with 6mM glacial acetic acid, add 200μl / well to 24-well plate, or add 400μl / well to 12-well plate, let stand at room temperature for 1 hour, wash 3-4 times with PBS, and store at 4-8℃. The coating method for 6-well plate is the same as above, with 800μl per well.

[0044] 5. Experimental steps

[0045] (1) Euthanize the mouse by CO2 asphyxiation (open the CO2 tank), remove the pancreas and place it in a 3 cm dish, and place it on ice (the pancreatic head may be connected to lymph nodes).

[0046] (2) Discard DPBS, add 5 ml of digestion solution I, and use a 5 ml syringe with a 1 ml needle to inject the liquid into the pancreas. Repeat several times.

[0047] (3) Transfer the pancreas to a 50 ml centrifuge tube, incubate at 37°C, and shake for 20 min. Discard the liquid, inject 8 ml of digestion solution II, and incubate at 37°C, and shake for 20 min.

[0048] (4) Wash twice with washing solution I (10 ml. The pancreas may become slag at this time. Centrifuge and pour out the liquid); discard the liquid, add 5 ml digestion solution III, incubate at 37°C, and shake for 20 minutes. (The time of this step can be adjusted according to the condition).

[0049] (5) After blowing the tissue into a slag-like state with a 1 ml pipette tip, filter the cells with a 70 μm mesh and slowly add the cells to a 15 ml centrifuge tube containing 6 ml of Wash Buffer II and centrifuge at 50 g for 5 min.

[0050] (6) Wash the cells twice with washing buffer II (about 10 ml), and centrifuge at 500 g for 5 min (changed to 250-300 g for 5 min).

[0051] (7) Using 1 ml of Waymouth complete culture, approximately 5×10^6 cells can be obtained.

[0052] (8) SEQ ID NO: 1 and SEQ ID NO: 2 (or SEQ ID NO: 3 and SEQ ID NO: 4) are mixed in equal proportions for transfection. During transfection, the cells can be placed in a dish, resuscitated in a cell culture incubator at 37°C for 2 hours using Waymouth medium, and transfected according to the suspension cell transfection method:

[0053] OPTI(100μl)+RNAiMAX(4μl)5min

[0054] OPTI (100 μl) + siRNA (4 μl) 5 min

[0055] After mixing, let stand for 5 minutes. According to the instructions of the transfection reagent, use 400 μl system for transfection and 500 μl system for cell culture, 1×10^4 cells / well in a 12-well plate.

[0056] 4-6 hours after transfection, collect the cells by centrifugation (speed: it is necessary to ensure that the cells can be collected by centrifugation; if the number of cells is small, they may not be visible).

[0057] The specific steps of the ADM observation experiment are as follows: when transfecting, use ordinary culture plates, add cells to the well plate containing 200ul OPTI, mix (100ul OPTI+4ul siRNA) and (100ul OPTI+4ul RNAiMAx) for 5 minutes and add them to the corresponding 24-well plate. After 4-6 hours in the incubator, collect the cells into 1.5ml EP tubes. Centrifuge and discard the supernatant, resuspend the cells to 500ul in waymouth complete medium containing TGF-α, transfer the cells to a 24-well plate pre-coated with collagen, divide them into three groups: NC, siSTAT5b-1 and si STAT5b-1, and culture them in the incubator. Observe the effect of siRNA on the ADM process at 24h and 48h.

[0058] The specific steps for RNA knockdown efficiency detection are as follows: the transfection steps are the same as above. When the cells are plated, 1×10^4 cells / well of acinar cells are plated in a well plate (12 or 6-well plate) pre-coated with collagen. After 24 hours, the cells are collected in Trizol, RNA is extracted by phenol chloroform method, and RNA is reversed by Takara reverse transcription reagent. Then, real-time PCR is performed using Takata's SubgreeSn to detect transfection efficiency, and actin is used as an internal reference.

[0059] The results are as follows Figure 1As shown in the figure, A represents the transformation process of acinar-like cluster to ductal-like cluster in the process of acinar ductal metaplasia. From the bar graph, it can be seen that at 24 and 48 hours, the proportion of acinar-like clusters in cells treated with siRNA increased compared with the control group, indicating that the transformation process of pancreatitis cancer was inhibited. Figure B shows that siRNA acts on Stat5b, resulting in a significant decrease in its transcription level, thereby affecting the progress of acinar ductal metaplasia, reducing the synthesis of ductal cells, and correspondingly, the ductal cell marker Krt19 is also reduced.

[0060] siRNA is a synthetic substance with the following sequence:

[0061] SEQ ID NO: 1 siRNA-1 GCCAAAGGAUGAAGUAUAUTT SEQ ID NO: 2 siRNA-2 AUAUACUUCAUCCUUUGGCTT SEQ ID NO: 3 siRNA-3 GCGUGAUGGAAGUAUUGAATT SEQ ID NO: 4 siRNA-4 UUCAAUACUUCCAUCACGCTT

Claims

1. An inhibitor of Stat5b expression, characterized in that The Stat5b expression inhibitor is siRNA; the sequence of the siRNA is shown in SEQ ID NOs. 1 and 2.

Citation Information

Patent Citations

  • Micromolecule selective depressant for STAT3 (Signal transducer and activator of transcription 3), as well as preparation method and applications thereof

    CN102219755A

  • Pancreatic cancer tumor marker and application thereof

    CN112362872A

  • Methods for the prophylactic treatment of cancer in patients suffering from pancreatitis

    WO2021001427A1